Last reviewed · How we verify
IBI308\oxaliplatin\capecitabine
At a glance
| Generic name | IBI308\oxaliplatin\capecitabine |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC (NA)
- Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer (PHASE3)
- Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer (PHASE2)
- Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients (PHASE1, PHASE2)
- Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer (PHASE2)
- A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) (PHASE3)
- Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer (PHASE3)
- First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI308\oxaliplatin\capecitabine CI brief — competitive landscape report
- IBI308\oxaliplatin\capecitabine updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI